Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:CERC NASDAQ:FBIO NASDAQ:NATR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.44+1.6%$4.37$3.04▼$5.10$863.24M0.621.81 million shs2.36 million shsCERCCerecor$14.41-9.5%$2.60$1.98▼$4.50$1.38B1.441.27 million shs1.58 million shsFBIOFortress Biotech$2.78+4.9%$2.58$1.67▼$4.53$88.03M1.16344,551 shs497,427 shsNATRNature's Sunshine Products$21.86-0.3%$24.80$12.97▼$28.14$385.64M0.9594,595 shs154,842 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+4.05%+1.39%-5.00%+3.07%+36.14%CERCCerecor0.00%0.00%0.00%-3.93%+260.25%FBIOFortress Biotech+4.74%+18.83%+14.22%-23.85%+51.43%NATRNature's Sunshine Products+1.53%-1.79%-18.99%-18.35%+49.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.44+1.6%$4.37$3.04▼$5.10$863.24M0.621.81 million shs2.36 million shsCERCCerecor$14.41-9.5%$2.60$1.98▼$4.50$1.38B1.441.27 million shs1.58 million shsFBIOFortress Biotech$2.78+4.9%$2.58$1.67▼$4.53$88.03M1.16344,551 shs497,427 shsNATRNature's Sunshine Products$21.86-0.3%$24.80$12.97▼$28.14$385.64M0.9594,595 shs154,842 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+4.05%+1.39%-5.00%+3.07%+36.14%CERCCerecor0.00%0.00%0.00%-3.93%+260.25%FBIOFortress Biotech+4.74%+18.83%+14.22%-23.85%+51.43%NATRNature's Sunshine Products+1.53%-1.79%-18.99%-18.35%+49.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.0012.61% UpsideCERCCerecor 0.00N/AN/AN/AFBIOFortress Biotech 2.25Hold$17.00511.51% UpsideNATRNature's Sunshine Products 3.00Buy$35.0060.11% UpsideCurrent Analyst Ratings BreakdownLatest NATR, ABUS, CERC, and FBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026FBIOFortress Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026NATRNature's Sunshine Products DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.005/8/2026NATRNature's Sunshine Products Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$37.004/20/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026FBIOFortress Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/20/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)3/16/2026FBIOFortress Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/12/2026NATRNature's Sunshine Products DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $33.003/10/2026NATRNature's Sunshine Products Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $29.002/23/2026FBIOFortress Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$14.08M62.29N/AN/A$1.32 per share3.36CERCCerecor$6.70M206.49N/AN/A$0.22 per share65.50FBIOFortress Biotech$63.26M1.46N/AN/A$6.09 per share0.46NATRNature's Sunshine Products$480.14M0.80$2.17 per share10.09$9.49 per share2.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.35N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)CERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AFBIOFortress Biotech$6.82M$3.170.881.84N/A193.12%109.66%45.56%N/ANATRNature's Sunshine Products$19.52M$1.1019.87N/AN/A4.06%14.67%9.27%7/30/2026 (Estimated)Latest NATR, ABUS, CERC, and FBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/7/2026Q1 2026NATRNature's Sunshine Products$0.2050$0.30+$0.0950$0.29$122.15 million$122.89 million3/31/2026Q4 2025ABUSArbutus BiopharmaN/A$0.87N/A$0.87N/A$179.13 million3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 million3/20/2026Q4 2025ABUSArbutus Biopharma-$0.0550-$0.01+$0.0450-$0.01$0.83 million$1.05 million3/10/2026Q4 2025NATRNature's Sunshine Products$0.19$0.30+$0.11$0.23$121.62 million$123.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26CERCCerecor0.792.192.18FBIOFortress Biotech0.182.862.77NATRNature's Sunshine ProductsN/A2.501.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%CERCCerecor62.84%FBIOFortress Biotech96.51%NATRNature's Sunshine Products79.40%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%CERCCerecor45.70%FBIOFortress Biotech28.50%NATRNature's Sunshine Products3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableNATRNature's Sunshine Products85017.58 million17.04 millionOptionableNATR, ABUS, CERC, and FBIO HeadlinesRecent News About These CompaniesNatures Sunshine Products Stock Dividends | NASDAQ:NATR | BenzingaMay 13, 2026 | benzinga.comNature's Sunshine Products (NASDAQ:NATR) Receives "Buy" Rating from DA DavidsonMay 12, 2026 | americanbankingnews.comNATR Q1 Deep Dive: Digital Channel Expansion and Margin Gains Shape OutlookMay 11, 2026 | finance.yahoo.comNature's Sunshine Products, Inc. Just Beat EPS By 41%: Here's What Analysts Think Will Happen NextMay 11, 2026 | finance.yahoo.comNature's Sunshine Products (NASDAQ:NATR) Given "Buy" Rating at DA DavidsonMay 11, 2026 | marketbeat.comNature’s Sunshine Products, Inc. (NASDAQ:NATR) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comNature's Sunshine’s (NASDAQ:NATR) Q1 CY2026: Beats On RevenueMay 8, 2026 | finance.yahoo.comNature's Sunshine targets $1B sales and 15% EBITDA margin as it reiterates 2026 $500M-$515M outlookMay 8, 2026 | msn.comNature's Sunshine Products Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comNature's Sunshine Products (NASDAQ:NATR) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPSMay 7, 2026 | marketbeat.comNature’s Sunshine Shareholders Approve 2026 Stock Incentive PlanMay 7, 2026 | tipranks.comNature's Sunshine Products, Inc. (NATR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comNature's Sunshine Products (NATR) Stock Rises on Q1 2026 EarningsMay 7, 2026 | quiverquant.comQNature's Sunshine Reports Strong First Quarter 2026 ResultsMay 7, 2026 | globenewswire.comNature's Sunshine (NATR) Q1 earnings report preview: What to look forMay 6, 2026 | msn.comWhat to Expect from Natures Sunshine Products Inc (NATR) Q1 2026 EarningsMay 6, 2026 | finance.yahoo.comNature’s Sunshine Appoints John Hnanicek as Chief Technology OfficerMay 1, 2026 | markets.businessinsider.comNature's Sunshine Appoints John Hnanicek as Chief Technology OfficerApril 30, 2026 | globenewswire.comNature's Sunshine Products (NATR) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comSkylands Capital LLC Trims Holdings in Nature's Sunshine Products, Inc. $NATRApril 28, 2026 | marketbeat.comHow The Growth Story Is Shaping Nature's Sunshine (NATR) And Its US$33 Valuation TargetApril 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent StocksBy Leo Miller | May 18, 2026NATR, ABUS, CERC, and FBIO Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.44 +0.07 (+1.60%) Closing price 04:00 PM EasternExtended Trading$4.45 +0.01 (+0.20%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Cerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Fortress Biotech NASDAQ:FBIO$2.78 +0.13 (+4.91%) Closing price 04:00 PM EasternExtended Trading$2.78 0.00 (-0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Nature's Sunshine Products NASDAQ:NATR$21.86 -0.07 (-0.32%) Closing price 04:00 PM EasternExtended Trading$21.88 +0.02 (+0.09%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
